SK pharmteco, a global CDMO, has opened its new cGMP plasmid suite at its facility in King of Prussia, PA. This strategic expansion enhances the company’s reliable and scalable supply of high-quality plasmids, a critical component in developing cell and gene therapies (CGTs).
SK pharmteco’s 300,000 sq. ft. King of Prussia facility offers a wide range of services, including process development and plasmid manufacturing with four dedicated suites capable of producing three distinct plasmid grades.
Additionally, the site features two independent aseptic fill & finish operations and provides integrated CDMO and contract analytical testing services, as well as an in-house CGMP cell line, further streamlining the development and manufacturing process for cell and gene therapies.
“This new CGMP plasmid suite in King of Prussia represents a solid investment in our capabilities and our commitment to the cell and gene therapy sector,” said Joerg Ahlgrimm, CEO at SK pharmteco. “We understand the vital role that high-quality plasmids play in developing these transformative medicines, and this expansion will enable us to serve our clients better and ultimately contribute to bringing these therapies to patients in need.”
